Guipavas

Electroconvulsive therapy (ECT) has been used since the 1930s primarily to treat drug-resistant depressive illnesses and has shown effectiveness in other psychiatric disorders. Despite its benefits, ECT can cause side effects, and in France, there is no current consensus on the best medical care for patients receiving this treatment. This project aims to identify how ECT is administered in France and to develop research that evaluates and improves its effectiveness based on updated healthcare models and national recommendations. The study focuses on observing and collecting data about ECT procedures in France without testing specific interventions or treatments. It seeks to understand current practices and patient outcomes to help maintain and enhance the guidance provided by the French National Agency for Accreditation and Evaluation in Health. Participants who are referred for ECT will be observed for treatment efficiency between 2018 and 2022. Researchers will monitor the therapeutic effects and side effects of ECT to assess its overall efficiency. The study involves tracking patient progress and outcomes to inform future recommendations and improve care standards.